<DOC>
	<DOCNO>NCT02662400</DOCNO>
	<brief_summary>India `` Diabetes Capital World '' 41 million Indians diabetes i.e . every fifth diabetic world Indian . Type 2 Diabetes Mellitus ( T2DM ) constitute major chunk diabetes insulin resistance hallmark feature pathogenesis . However , progression disease insulin resistance become stable whereas β - cell function show gradual decline due ongoing apoptosis . This ultimately lead inability β - cell cope increase demand insulin cause due insulin resistance manifest hyperglycemia . As β - cell failure progressive inexorable , demonstrate United Kingdom Prospective Diabetes Study , patient T2DM would eventually require insulin would difficult achieve attain strict glycemic control . It well know diabetes related complication account morbidity mortality disease prevent delayed strict glycemic control . However , even intensive insulin therapy show glycemic control never perfect patient exhibit hyperglycemia hypoglycemia 24 hour glucose profile . Also insulin therapy physiological hepatic `` first - pas '' metabolism insulin require halt hepatic glucose output , responsible fast hyperglycemia . This lead researcher evolve various strategy β - cell replacement therapy e.g . pancreatic transplantation islet cell transplantation . Initially result islet cell transplantation dismal induction glucocorticoid free immunosuppressive therapy use adequate number islet cell multiple donor , result islet cell transplantation well . However , islet cell transplantation limitation viz insufficient supply , technically demand requirement lifelong immunosuppressive therapy recipient .</brief_summary>
	<brief_title>Assessment Insulin Sensitivity β Cell Function Clamps Studies</brief_title>
	<detailed_description>The shortcoming overcome use stem cell inexhaustible source β -cells . Stem cell primitive cell capable differentiating mature cell body various lineage . Stem cell obtain various source like blastocyst ( embryonal stem cell ) , umbilical cord bone marrow . There evidence suggest stem cell transplantation lead improvement pancreatic endocrine function improvement glycemic control diabetic mice various mechanism transdifferentiation regeneration endothelial cell damage islet turn lead regeneration islet cell paracrine action . However , till date study demonstrate stem cell therapy effective patient T2DM glycemic control . The investigator propose carry autologous bone marrow - derived stem cell transplantation ( ABMSCT ) patient T2DM , obtain bone marrow superselective injection gastroduodenal artery purification without immunosuppressive regimen .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Failure triple oral hypoglycemic agent stable dos insulin least 3 month . On vildagliptin , pioglitazone metformin least 3 month along Insulin maintain euglycemia . HbA1c &lt; 7.5 % . Insulin requirement ≥0.4 IU/kg/d . GAD antibody negative status . Patients type 1 diabetes mellitus secondary diabetes . Patients serum creatinine &gt; 1.5 mg/dl . Abnormal liver function test ( define value transaminases &gt; 3 time upper value normal serum bilirubin high normal reference value laboratory ) . History cholecystitis/ cholelithiasis/cholecystectomy . Seropositivity HIV , HBsAg hepatitis C virus ( HCV ) . History myocardial infarction unstable angina previous 3 month . History malignancy . Patients active infection .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>